Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Comment by kuatoliveson Mar 15, 2017 12:37pm
154 Views
Post# 25982800

RE:RE:RE:RE:RE:RE:RE:ARLZ will be discounted to cash

RE:RE:RE:RE:RE:RE:RE:ARLZ will be discounted to cashI hope it comes back for the sake of the other shareholders, but my confidence was just shattered. My instincts tell me to get out, so I'm going to listen.

My big fear is that Yosprala won't get adopted beyond a first prescription tryout as the doctor's go "Hey, give this a try," and the patient does, but doesn't renew the script because renewing scripts is a big pain - when you  can just go down to the grocery store when you get around to it and pick up some aspirin and omnepezole without a script. Also:

-No confidence in Harris having destroyed his shareholder's capital.
-Deerfield could write off the whole adventure at any time.
-Insider selling
-ARLZ is a one trick pony, and if that pony breaks its leg, it's over.
-Bad blood over Tribute
-Much better personal success on Venture stocks. Heading back there....





<< Previous
Bullboard Posts
Next >>